Mohamad Sabbah

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Journal: Bone marrow transplantation

Published: March 02, 2026

Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France.

Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France.

Journal: Cytotherapy

Published: December 16, 2025

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Journal: Bone marrow transplantation

Published: June 20, 2025

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?

Journal: Bone marrow transplantation

Published: June 20, 2025

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.

Journal: Bone marrow transplantation

Published: August 10, 2024

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?

Journal: Cancers

Published: July 02, 2022

N,N'-alkylated Imidazolium-derivatives act as quorum-sensing inhibitors targeting the Pectobacterium atrosepticum-induced symptoms on potato tubers.

N,N'-alkylated Imidazolium-derivatives act as quorum-sensing inhibitors targeting the Pectobacterium atrosepticum-induced symptoms on potato tubers.

Journal: International journal of molecular sciences

Published: May 31, 2013

Synthesis and biological evaluation of new N-acyl-homoserine-lactone analogues, based on triazole and tetrazole scaffolds, acting as LuxR-dependent quorum sensing modulators.

Synthesis and biological evaluation of new N-acyl-homoserine-lactone analogues, based on triazole and tetrazole scaffolds, acting as LuxR-dependent quorum sensing modulators.

Journal: Bioorganic & medicinal chemistry

Published: February 21, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026